# Cardiovascular risk factors and events in a district general Haematology population undergoing cytotoxic chemotherapy

Dr Jonathan Bennett, Dr Sothinathan Gurunathan, Dr Jack Baker, Dr Lydia Jones Epsom & St Helier NHS Trust

#### Introduction:

There is increasing attention to the cardiovascular impact of cytotoxic chemotherapy. The European Society of Cardiology has defined the baseline risk factors for cardiotoxicity<sup>1</sup> alongside their position paper on Cardio-oncology. Within our district general haematology population the burden of these risk factors is unknown.

#### Methods:

Retrospective analysis of 100 consecutive patients commenced on chemotherapy in the last year at Epsom & St Helier NHS Trust, London, UK. We reviewed the notes for pre-existing cardiovascular risk factors and disease. We followed them to assess for cardiovascular events.

#### Results:


# Demographics:

Median age (IQR): 73 (61-81)

Male sex: 60% Caucasian ethnicity: 85%

Median follow up (days): 219 (31-339)

Total cases:	100
Myeloma:	45%
Leukaemia:	18%
Lymphoma:	37%



## Pre-existing cardiac disease:

Heart failure: 7%

Coronary artery disease: 16%

Atrial fibrillation: 12%

Ventricular tachycardia: 1%

## Pre-existing Cardiovascular Risk Factors:

**Hypertension:** 50%

Hypercholesterolaemia: 45%

Diabetes: 28%

Active or ex-smoker: 43%

Excess alcohol intake:


8%

## Cardiovascular events during treatment:

New atrial fibrillation:	2%
Acute coronary	1%
syndrome:	
Acute heart failure:	3%
Non-specific chest pain:	2%
Total mortality:	15%
Cardiovascular mortality:	1%
Cardiovascular hospital	4%
admission.	

#### Risk factor burden and cardiovascular events:

Patients that had cardiovascular events had significantly (P=0.01) higher burden of pre-existing risk factors and cardiac disease.



#### Conclusions:

There is a moderate burden of cardiac disease and risk factors in our population. Cardiovascular events are uncommon, but occur predictably in those with pre-existing disease and risk factors. Additional care should be taken in those patients when prescribing chemotherapy.





